OrganOx Limited is a research and experimental development company specializing in liver transplantation with normothermic perfusion. Established in 2008 and currently active, OrganOx focuses on enhancing the preservation and improving patient outcomes through innovative medical technologies. The company’s core expertise lies in optimizing the process of liver transplantation, a complex procedure requiring meticulous preservation and careful management of the patient’s condition. OrganOx’s primary service is the development and refinement of normothermic perfusion technology, a method utilizing extreme heat to significantly extend the viability of the transplanted liver. This technology aims to minimize organ damage and improve long-term survival rates for patients undergoing liver transplantation. The company’s research encompasses a broad range of scientific disciplines, including biomedical engineering, physiology, and pathology. OrganOx operates within the SIC codes of 72190 – Other research and experimental development on natural sciences and engineering, and is classified as a limited company (Ltd). The company’s international presence is currently non-existent, and it employs a workforce of individuals with a high level of skill and dedication. The company’s focus is on global business mobility, specifically targeting Senior or Specialist Worker visas. Its activities are aligned with advancements in global healthcare.

OrganOx Limited is a research and experimental development company specializing in liver transplantation with normothermic perfusion. Established in 2008 and currently active, OrganOx focuses on enhancing the preservation and improving patient outcomes through innovative medical technologies. The company’s core expertise lies in optimizing the process of liver transplantation, a complex procedure requiring meticulous preservation and careful management of the patient’s condition. OrganOx’s primary service is the development and refinement of normothermic perfusion technology, a method utilizing extreme heat to significantly extend the viability of the transplanted liver. This technology aims to minimize organ damage and improve long-term survival rates for patients undergoing liver transplantation. The company’s research encompasses a broad range of scientific disciplines, including biomedical engineering, physiology, and pathology. OrganOx operates within the SIC codes of 72190 – Other research and experimental development on natural sciences and engineering, and is classified as a limited company (Ltd). The company’s international presence is currently non-existent, and it employs a workforce of individuals with a high level of skill and dedication. The company’s focus is on global business mobility, specifically targeting Senior or Specialist Worker visas. Its activities are aligned with advancements in global healthcare.